{
  "data": {
    "id": "stat_HEV6X9524JMG0W909PSF771HMW",
    "url": "https://statorigin.org/stat/stat_HEV6X9524JMG0W909PSF771HMW",
    "indicator": {
      "slug": "core-operating-profit-growth-quarterly",
      "name": "Core operating profit growth (quarterly)",
      "definition": "Quarterly percentage change in core operating profit."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "period": {
      "start": "2026-04-01",
      "end": "2026-06-30",
      "type": "quarter"
    },
    "value": 7,
    "value_text": "+7%",
    "unit": "percent",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "GSK",
      "org_short_name": "GSK",
      "org_url": "https://www.gsk.com",
      "org_tier": 2,
      "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026",
      "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/",
      "document_type": "press_release",
      "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth",
      "quote": "Core operating profit +7% and Core EPS +9% reflecting higher sales and favourable product and regional mix, partly offset by increased investment in R&D and new asset launches and lower royalty income",
      "published_date": null,
      "accessed_at": "2026-09-17",
      "license": "see-source",
      "url_status": "ok"
    },
    "verification": "verified",
    "verified_by": "seed:auto-extract-v1",
    "verified_at": "2026-09-17T07:16:01.811Z",
    "confidence": 0.9,
    "is_secondhand": false,
    "supersedes": null,
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_HEV6X9524JMG0W909PSF771HMW",
      "bibtex": "@misc{gsk2026core771hmw,\n  author       = {{GSK}},\n  title        = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_HEV6X9524JMG0W909PSF771HMW},\n  note         = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}"
    },
    "updated_at": "2026-09-17T07:16:01.811Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}